Matteo Burigotto

Matteo Burigotto

Auto-generated profile, based on publicly available information

Matteo Burigotto

Armenise-Harvard Laboratory of Cell Division, Department of Cellular, Computational and Integrative Biology - CIBIO, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ZWZilu Wang
Zilu Wang
MBMatteo Burigotto
Matteo Burigotto
SGSabrina Ghetti
Sabrina Ghetti
FVFrançois Vaillant
François Vaillant
TTTao Tan
Tao Tan
ASAndreas Strasser
Andreas Strasser
Mutations in the tumor suppressor TP53 cause cancer and impart poor chemotherapeutic responses, reportedly through loss-of-function, dominant-negative effects and gain-of-function (GOF) activities. The relative contributions of these attributes is unknown. We found that removal of 12 different TP53 mutants with reported GOFs by CRISPR/Cas9 did not impact proliferation and response to chemotherapeutics of 15 human cancer cell lines and colon cancer–derived organoids in culture. Moreover, removal of mutant TP53/TRP53 did not impair growth or metastasis of human cancers in immune-deficient mice or growth of murine cancers in immune-competent mice. DepMap mining revealed that removal of 158 different TP53 mutants had no impact on the growth of 391 human cancer cell lines. In contrast, CRISPR-mediated restoration of wild-type TP53 extinguished the growth of human cancer cells in vitro. These findings demonstrate that LOF but not GOF effects of mutant TP53/TRP53 are critical to sustain expansion of many tumor types. Significance: This study provides evidence that removal of mutant TP53, thereby deleting its reported GOF activities, does not impact the survival, proliferation, metastasis, or chemotherapy responses of cancer cells. Thus, approaches that abrogate expression of mutant TP53 or target its reported GOF activities are unlikely to exert therapeutic impact in cancer. See related commentary by Lane, p. 211 . This article is featured in Selected Articles from This Issue, p. 201

22 December 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
MBMatteo Burigotto
Matteo Burigotto
AMAlessia Mattivi
Alessia Mattivi
DMDaniele Migliorati
Daniele Migliorati
GMGiovanni Magnani
Giovanni Magnani
CVChiara Valentini
Chiara Valentini
LFLuca L Fava
Luca L Fava
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 June 2021 in STAR Protocols
Verified
Journal Article
Open access
SGSabrina Ghetti
Sabrina Ghetti
MBMatteo Burigotto
Matteo Burigotto
AMAlessia Mattivi
Alessia Mattivi
GMGiovanni Magnani
Giovanni Magnani
ACAntonio Casini
Antonio Casini
LFLuca L. Fava
Luca L. Fava
HTERT-RPE1 cells are genetically stable near diploid cells widely used to model cell division, DNA repair, or ciliogenesis in a non-transformed context. However, poor transfectability and limited homology-directed repair capacity hamper their amenability to gene editing. Here, we describe a protocol for rapid and efficient generation of diverse homozygous knockins. In contrast to other approaches, this strategy bypasses the need for molecular cloning. Our approach can also be applied to a variety of cell types including cancer and induced pluripotent stem cells (iPSCs).

27 October 2023 in EMBO Reports
Verified
Journal Article
Open access
MBMatteo Burigotto
Matteo Burigotto
VVVincenza Vigorito
Vincenza Vigorito
CGColin Gliech
Colin Gliech
AMAlessia Mattivi
Alessia Mattivi
SGSabrina Ghetti
Sabrina Ghetti
LFLuca L Fava
Luca L Fava
53BP1 acts at the crossroads between DNA repair and p53‐mediated stress response. With its interactors p53 and USP28, it is part of the mitotic surveillance (or mitotic stopwatch) pathway (MSP), a sensor that monitors the duration of cell division, promoting p53‐dependent cell cycle arrest when a critical time threshold is surpassed. Here, we show that Polo‐like kinase 1 (PLK1) activity is essential for the time‐dependent release of 53BP1 from kinetochores. PLK1 inhibition, which leads to 53BP1 persistence at kinetochores, prevents cytosolic 53BP1 association with p53 and results in a blunted MSP. Strikingly, the identification of CENP‐F as the kinetochore docking partner of 53BP1 enabled us to show that measurement of mitotic timing by the MSP does not take place at kinetochores, as perturbing CENP‐F‐53BP1 binding had no measurable impact on the MSP. Taken together, we propose that PLK1 supports the MSP by generating a cytosolic pool of 53BP1 and that an unknown cytosolic mechanism enables the measurement of mitotic duration.

26 November 2025 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
MBM. Burigotto
M. Burigotto
JCJ. G. Carlton
J. G. Carlton
The endosomal sorting complex required for transport (ESCRT) machinery is an evolutionarily conserved multisubunit protein complex that remodels cellular membranes. Beyond its classical role in endosomal sorting, the ESCRT machinery has been implicated in an ever-growing number of functions, including viral budding, cytokinesis, autophagy, extracellular vesicle release, pruning of synaptic processes and the repair and closure of holes in cellular membranes. Membrane remodelling functions are typically ascribed to the ESCRT-III subcomplex. In this Review, we discuss recent mechanistic and structural insights into how these proteins assemble and are remodelled to achieve membrane severing. We focus particularly on how ESCRT-III is engaged at different subcellular compartments during both interphase and mitosis to repair and remodel membranes.

28 March 2021 in Molecular & Cellular Oncology
Verified
Journal Article
Closed access
MBMatteo Burigotto
Matteo Burigotto
LFLuca L. Fava
Luca L. Fava
The PIDDosome is a Caspase-2-activating platform assembling in response to centrosome amplification or genotoxic stress. We have recently shown that both stimuli depend on ANKRD26 (ankyrin repeat domain-containing protein 26)-mediated localization of PIDD1 (p53-inducible protein with death domain) at the centrosome, demonstrating how this organelle can directly influence cell fate.